Li Cuiping, Liu Yun, Hu Zhen, Zhou Yang
School of Public Health, Guangxi Medical University , Nanning , P. R. China.
Leuk Lymphoma. 2014 Jun;55(6):1309-19. doi: 10.3109/10428194.2013.835404. Epub 2013 Oct 24.
Studies on gene polymorphisms of RAD51 and X-ray repair cross-complementing group 3 (XRCC3) and acute myeloid leukemia risk (AML) are conflicting and there is no recent meta-analysis. Therefore, the purpose of this study was to evaluate the effect of RAD51 G135C and XRCC3 Thr241Met genotypes on AML susceptibility. We conducted a systematic search of three databases including PubMed and EMBASE for the period up to 20 February 2013 and identified 43 relevant studies. Six eligible studies were eventually selected for RAD51 (1764 cases and 3469 controls) and six studies for XRCC3 (1352 cases and 2582 controls). Pooled odds ratios (ORs) and 95% confidence intervals (CIs) for the risk of AML associated with RAD51 and XRCC3 were appropriately calculated based on fixed- or random-effects models. The quality of studies was evaluated using the Newcastle-Ottawa Scale (NOS). Subgroup analyses were performed among Asian, Caucasian and other populations. The pooled results showed that the leukemia risk was not significantly associated with RAD51: the same results were obtained among any subgroup analysis. No significant association was demonstrated for AML risk with XRCC3 in the total population, but elevated associations were observed in Caucasians for the homozygote and recessive comparison (Met/Met vs. Thr/Thr, OR = 1.67, 95% CI = 1.09-2.57, p = 0.019; recessive model, OR = 1.78, 95% CI = 1.19-2.65, p = 0.005). This meta-analysis provides evidence that the RAD51 and XRCC3 polymorphisms are not associated with an increased risk of AML in the total population.
关于RAD51和X射线修复交叉互补基因3（XRCC3）的基因多态性与急性髓系白血病（AML）风险的研究结果相互矛盾，且近期尚无荟萃分析。因此，本研究旨在评估RAD51 G135C和XRCC3 Thr241Met基因型对AML易感性的影响。我们对包括PubMed和EMBASE在内的三个数据库进行了系统检索，检索时间截至2013年2月20日，共识别出43项相关研究。最终选取了6项符合条件的RAD51研究（1764例病例和3469例对照）以及6项XRCC3研究（1352例病例和2582例对照）。基于固定效应或随机效应模型，适当计算了与RAD51和XRCC3相关的AML风险的合并比值比（OR）和95%置信区间（CI）。使用纽卡斯尔-渥太华量表（NOS）评估研究质量。在亚洲、白种人和其他人群中进行了亚组分析。合并结果显示，白血病风险与RAD51无显著关联：在任何亚组分析中均得到相同结果。在总体人群中，未证明XRCC3与AML风险有显著关联，但在白种人中，纯合子和隐性比较显示关联增加（Met/Met vs. Thr/Thr，OR = 1.67，95% CI = 1.09 - 2.57，p = 0.019；隐性模型，OR = 1.78，95% CI = 1.19 - 2.65，p = 0.005）。这项荟萃分析提供了证据，表明RAD51和XRCC3多态性与总体人群中AML风险增加无关。
